Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7521866 | 0.87 | CCR2 (0.43) | HPGDMAPTALDH1A1TSHREPHX2 | |
| SCHEMBL7522219 | 0.86 | CCR2 (0.43) | HPGDMAPTALDH1A1EPHX2CCR2 | |
| SCHEMBL6813763 | 0.82 | CA12 (0.54) | HPGDMAPTALDH1A1TSHRCCR2 | |
| SCHEMBL7520262 | 0.81 | CCR2 (0.48) | HPGDALDH1A1CCR2SMN1; SMN2L3MBTL1 | |
| SCHEMBL8837220 | 0.81 | CCR2 (0.48) | HPGDALDH1A1CCR2SMN1; SMN2L3MBTL1 | |
| SCHEMBL7529482 | 0.81 | SLC1A2 (0.45) | HPGDMAPTALDH1A1TSHRSLC1A2 | |
| SCHEMBL1710436 | 0.79 | CCR2 (0.48) | HPGDALDH1A1TSHREPHX2CCR2 | |
| SCHEMBL8837195 | 0.78 | NPSR1 (0.55) | HPGDALDH1A1TSHRCCR2SMN1; SMN2 | |
| SCHEMBL8837129 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1CCR2SMN1; SMN2POLB | |
| SCHEMBL8837111 | 0.76 | CCR2 (0.56) | EPHX2CCR2SMN1; SMN2POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0400440-B1 | Amino acid derivative anticonvulsant | RES CORP TECHNOLOGIES INC (US) | 2002-03-13 | — | — | EP | claimed |
| US-5378729-A | Diamide derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-01-03 | — | — | US | claimed |
| WO-1990015069-A2 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1990-12-13 | — | — | WO | claimed |
| EP-0400440-A1 | Amino acid derivative anticonvulsant | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-2035029-B1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | UCB PHARMA GMBH (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-9446011-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (CZ) | 2016-09-20 | — | — | US | disclosed |
| US-9308183-B2 | Therapy for hyperexcitability disorders | UCB PHARMA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2992891-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BRIVARACETAM AND LACOSAMIDE WITH SYNERGISTIC ANTICONVULSANT EFFECT | UCB Pharma GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9095557-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150202184-A1 | ANTICONVULSANT COMBINATION THERAPY | SCHWARZ PHARMA AG (DE) | 2015-07-23 | — | — | US | disclosed |
| US-8828943-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2046386-B1 | PEPTIDE COMPOUNDS FOR THE TREATMENT OF SKELETAL MUSCLE DISORDERS ASSOCIATED WITH ION CHANNEL DYSFUNCTION | UCB PHARMA GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-1873527-A1 | Method for identifying CRMP modulators | SCHWARZ PHARMA AG (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007144195-A2 | PHARMACEUTICAL COMPOSITION WITH SYNERGISTIC ANTICONVULSANT EFFECT | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144196-A2 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-0400440-B1 | Amino acid derivative anticonvulsant | RES CORP TECHNOLOGIES INC (US) | 2002-03-13 | — | — | EP | disclosed |
| US-5654301-A | Lacosamide FDA Orange book listed patent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5378729-A | Diamide derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1992021648-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0400440-A1 | Amino acid derivative anticonvulsant | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202184-A1 | ANTICONVULSANT COMBINATION THERAPY | VIP, GABRE, GABRB2 | HPGD 1944/4885MAPT 388/4885ALDH1A1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.